Follow The Filings

CTMX Cytomx Therapeutics Inc.

Health Care, filed as CYTOMX THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.3%
  • $1.6M
  • 1 add

In 2026 Q2 Nathan Fischel added to Cytomx Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Add 0.31%

Who owns CTMX

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.31%, was 0.24% Add +90.6% 438,407 $1.6M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CTMX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CTMX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $462K sold by 1 insider under 10b5-1 plans
  1. Sean A. McCarthy CEO
    Planned sale
    $462K 101,793 shares at $4.54 8.5% of stake
    Traded Nov 6, 2025 Filed Oct 16
    ↗

Also filed in the last 12 months, not counted as buying or selling: 6 stock grants, 5 sales to cover taxes, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02 Filing Doc
8-K 5.02,5.03,5.07,9.01 Filing Doc
8-K 1.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated 4 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $101.21M $138.1M $76.2M
Net income -$0.569M $31.87M -$17.37M
Net margin * -0.6% 23.1% -22.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $182.94M $107.3M $143.92M
Total non-current assets * $18.86M $13.23M $7.64M
Total assets $201.79M $120.53M $151.57M
Total current liabilities $155.91M $85.77M $46.62M
Total non-current liabilities * $93.33M $35.22M $5.94M
Total equity -$47.45M -$0.456M $99.01M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$56.04M -$86.23M -$75.59M
Cash from investing -$150.67M $99.7M -$59.74M
Cash from financing $30.23M $7.52M $110.45M
Net change in cash * -$176.48M $20.99M -$24.88M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.